SLC5A2 and heart failure: Furthermore, the ongoing DAPAgliflozin on the prognosis of patients with acute Myocardial Infarction (DAPA-MI) and EMPAgliflozin on hospitalization for heart failure and mortality in patients with aCuTe myocardial infarction (EMPACT-MI) trials will shed the light on the efficacy and safety of SGLT-2 inhibitors in patients with new cardiac dysfunction after MI [41].